Quote | Cardiff Oncology Inc. (NASDAQ:CRDF)
Last: | $2.08 |
---|---|
Change Percent: | 0.0% |
Open: | $2.05 |
Close: | $2.08 |
High: | $2.1525 |
Low: | $2.03 |
Volume: | 728,089 |
Last Trade Date Time: | 07/02/2024 03:00:00 am |
News | Cardiff Oncology Inc. (NASDAQ:CRDF)
2024-05-21 23:22:53 ET Summary Cardiff Oncology's Onvansertib is a first-in-class oral PLK1 inhibitor that targets difficult-to-treat cancers such as mCRC, mPDAC, SCLC, and TNBC. Onvansertib's promising early data suggest that it overcomes treatment resistance, improves response r...
SAN DIEGO, May 13, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will present at two upcoming investor conferences in M...
Message Board Posts | Cardiff Oncology Inc. (NASDAQ:CRDF)
Subject | By | Source | When |
---|---|---|---|
znewcar1: $CRDF 22% v1,2M c1.91 f44,677M H1.92 ML1.2 YL1.54 BO1.7& pushed to hod | znewcar1 | investorshangout | 01/18/2023 11:12:04 PM |
znewcar1: CRDF 35% v8,8M c2.25 f43,3M H2.42 BO1.7 and pushed to HOD | znewcar1 | investorshangout | 06/09/2022 9:49:50 PM |
znewcar1: CRDF 25% v1,6M c1.70 f43,3M H1.73 MH1.13 BO1.4 and pushed | znewcar1 | investorshangout | 06/08/2022 3:14:09 AM |
Baird apparently think it is worthwhile to remain | oxnous | investorshub | 01/19/2022 8:52:05 PM |
So did people not think the data was | pipette | investorshub | 01/19/2022 2:13:47 AM |
News, Short Squeeze, Breakout and More Instantly...
Cardiff Oncology Inc. Company Name:
CRDF Stock Symbol:
NASDAQ Market:
Cardiff Oncology Inc. Website:
SAN DIEGO, May 13, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will present at two upcoming investor conferences in M...
- In RAS-mutated mCRC, clinical data from ONSEMBLE trial, and preclinical data presented at AACR, demonstrated strong efficacy signal in bev naïve patients and support ongoing first-line RAS-mutated mCRC lead program - - In RAS wild-type mCRC, preclinical data presented at AACR dem...